Dale Stovall, MD
Obstetrics & Gynecology · Dallas, TXNPI 1962592485
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $476,089 of the $590,428 with a category attached, or 80.6%. 31 manufacturers reported payments, led by AbbVie at 42.3% of the total. Among obstetrics & gynecology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 697 payments — averaging $847.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$250K
- Mayne Pharma Commercial LLC$229K
- Myovant Sciences Inc.$40K
- Bayer$32K
- Astellas Pharma US Inc$15K
- Sumitomo Pharma America, Inc.$11K
- plus $15K from 25 others
What the payments were for
- Consulting fees$33,1246%
- Speaking & faculty fees$476,08981%
- Travel & lodging$62,57211%
- Food & beverage$18,6433%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 290 | $249,792 |
| Mayne Pharma Commercial LLC | 204 | $228,675 |
| Myovant Sciences Inc. | 47 | $39,781 |
| Bayer | 52 | $31,791 |
| Astellas Pharma US Inc | 19 | $14,956 |
| Sumitomo Pharma America, Inc. | 14 | $10,711 |
| Pfizer | 8 | $5,852 |
| Organon | 18 | $3,728 |
| Shield Therapeutics Inc | 3 | $2,078 |
| Merck | 4 | $1,400 |
| Fujirebio Diagnostics, Incorporated | 2 | $725 |
| Davol Inc. | 4 | $160 |
| Coopersurgical, Inc. | 2 | $114 |
| Gen-probe, Inc. | 1 | $107 |
| Johnson & Johnson | 5 | $98 |
| CSL Behring | 3 | $54 |
| Myovant Sciences GmbH | 1 | $49 |
| KCI USA, Inc. | 3 | $46 |
| Evofem Biosciences, Inc. | 2 | $44 |
| Hologic Sales And Service, LLC | 2 | $39 |
| Mallinckrodt Enterprises LLC | 2 | $34 |
| Pacira Pharmaceuticals Incorporated | 2 | $31 |
| Astellas Pharma Global Development | 1 | $29 |
| Meditrina | 1 | $21 |
| Mission Pharmacal Company | 1 | $21 |
| Exeltis, USA Inc. | 1 | $21 |
| AstraZeneca | 1 | $20 |
| Smith+Nephew | 1 | $16 |
| Minerva Surgical, Inc | 1 | $14 |
| Mallinckrodt Hospital Products Inc. | 1 | $12 |
| Channel Medsystems, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orilissa$166,490
- ANNOVERA$111,637
- NEXTSTELLIS$97,000
- ORIAHNN$70,872
- MYFEMBREE$55,556
- Kyleena$14,015
- Veozah$13,912
- BIJUVA$12,309
- NEXPLANON$4,125
- ACCRUFER$1,900
- JADA SYSTEM$164
- Aptima HPV$107
- co testing$107
- Aptima M genitalium$107
- Vaginitis$107
How this compares
$590,428 in reported general payments places this provider in the 95th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other obstetrics & gynecology in Dallas
- Quanita CrableDallas$176K
- Kamilia SmithDallas$119K
- Yolanda LawsonDallas$96K
- Patrick WeixDallas$96K
- David RogersDallas$44K
- Devin GarzaAustin$2M
- Shawn TassoneAustin$1.3M
- Karyn-Anne CumberbatchMissouri City$452K
- Robert AsgharianEl Paso$366K
- Catherine HansenWebster$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.